Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
BigH3 Is a Promising Biomarker in NSLC Patients
April 5, 2024
Proteolytic degradation of BigH3 can be quantified non-invasively in serum with biomarker potential for patients with non-small cell lung cancer
Introduction
Transforming growth factor beta induced protein ig-h3 (BigH3/TGFBI) is widely expressed and is participating in various biological processes including adhesion, migration, and angiogenesis. BigH3 is known to bind multiple collagens and are often embedded in the matrix where it seems
to function as a linker between ECM and cell surfaces. In non-small cell lung cancer (NSCLC), the increased proteolytic activity found may degrade BigH3, disrupting its ECM interactions and generating peptide fragments that could potentially serve as novel non-invasive biomarkers if released into circulation.
Our aim is to develop a tool to quantify degraded BigH3 non-invasively and explore its potential as a biomarker in NSCLC.
Poster
Conclusion
Degradation of BIGH3 can be reflected by non-invasive quantification of the cleaved fragment of BigH3,
BigH3M-N, in serum. This suggests BigH3M-N as a promising biomarker in NSCLC with potential for discriminating between subtypes. However, as BigH3M-N is connected to fibroblast matrix biology, the optimal use for this biomarker might be in combination with other ECM biomarkers.
